What's Happening?
Oslo-based Circio has entered into a collaboration with the Universidad de Santiago de Compostela (USC) in Spain, through USC's TraffikGene project, to advance the non-viral delivery of circVec circular RNA expression vectors. This partnership aims to enhance
next-generation gene and cell therapies by combining Circio's circular RNA expression technology with TraffikGene's peptide amphiphile carrier system. The collaboration will focus on high-throughput screening of circVec delivery, aiming to optimize formulations for efficient and targeted delivery into specific cell and tissue types. The project will proceed in three stages: initial in vitro screening of peptide carriers with non-viral circVec vectors, physicochemical optimization of lead formulations, and in vivo evaluation in mouse models to assess expression kinetics and delivery efficacy.
Why It's Important?
This collaboration is significant as it represents a step forward in the development of non-viral delivery systems for gene therapy, which could potentially overcome some of the limitations associated with viral vectors, such as immune responses and limited targeting capabilities. By enhancing the delivery and targeting of circular RNA vectors, this partnership could lead to more effective and safer gene therapies. The ability to target specific tissues with precision could open new therapeutic avenues and improve the treatment of various genetic disorders. The collaboration also highlights the growing importance of international partnerships in advancing biotechnological innovations.
What's Next?
The collaboration will move forward with the planned stages of research, starting with in vitro screenings and progressing to in vivo evaluations. The outcomes of these studies will determine the efficacy and potential of the non-viral delivery system. If successful, this could lead to further development and eventual clinical trials, potentially transforming the landscape of gene therapy. Stakeholders in the biotechnology and pharmaceutical industries will likely monitor the progress closely, as successful outcomes could lead to new partnerships and investments in similar technologies.
